Appears On
Episode Appearances
The Top Line · Jul 10, 2026
A $10B deal, China trial scrutiny and highlights from ADA 2026
“Discussed company positioning, oral obesity pill success, and confidence in Novo's market leadership at ADA”
Vertex Crinetics acquisition and rare endocrine disease expansionClinical trial regulation and China data integrity scrutinyGLP-1 agonist efficacy and weight loss outcomes
View Analysis